Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Effect of a chamomile extract in protecting against radiation-induced intestinal mucositis.

Khayyal MT, Kreuter MH, Kemmler M, Altmann P, Abdel-Naby DH, El-Ghazaly MA.

Phytother Res. 2019 Jan 10. doi: 10.1002/ptr.6263. [Epub ahead of print] No abstract available.

PMID:
30632234
2.

The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study.

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C.

Eur Respir J. 2018 Dec 21. pii: 1801587. doi: 10.1183/13993003.01587-2018. [Epub ahead of print]

PMID:
30578385
3.

Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.

Holtze C, Flaherty K, Kreuter M, Luppi F, Moua T, Vancheri C, Scholand MB.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180078. doi: 10.1183/16000617.0078-2018. Print 2018 Dec 31. Review.

4.

Transbronchial Cryobiopsies for Diagnosing Interstitial Lung Disease: Real-Life Experience from a Tertiary Referral Center for Interstitial Lung Disease.

Wälscher J, Groß B, Eberhardt R, Heussel CP, Eichinger M, Warth A, Lasitschka F, Herth FJF, Kreuter M.

Respiration. 2018 Dec 14:1-7. doi: 10.1159/000493428. [Epub ahead of print]

PMID:
30554201
5.

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events.

Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, Melgaard Nielsen K, Münster AB, Myllärniemi M, Ravaglia C, Vanuytsel T, Wijsenbeek M.

Respiration. 2018 Dec 13:1-12. doi: 10.1159/000495046. [Epub ahead of print] Review.

PMID:
30544129
6.

[Sirolimus for LAM - A New MILEStone Reached?]

Kreuter M, Wirtz H.

Pneumologie. 2019 Jan;73(1):22-23. doi: 10.1055/a-0802-3633. Epub 2018 Dec 12. German. No abstract available.

PMID:
30541159
7.

Disseminating a Smoke Free Homes program to low SES households in the US through 2-1-1: Results of a national impact evaluation.

Bundy LT, Haardörfer R, Kegler MC, Owolabi S, Berg CJ, Escoffery C, Thompson T, Mullen PD, Williams R, Hovell M, Kahl T, Harvey D, Price A, House D, Booker BW, Kreuter MW.

Nicotine Tob Res. 2018 Dec 5. doi: 10.1093/ntr/nty256. [Epub ahead of print]

PMID:
30517679
8.

Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD.

Flechsig P, Hural O, Kreuter M, Eichhorn M, HEUßEL G, Sachpekidis C, Kauczor HU, Haberkorn U, Heussel CP, Eichinger M.

In Vivo. 2018 Nov-Dec;32(6):1457-1462. doi: 10.21873/invivo.11399.

PMID:
30348701
9.

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies.

Wang Z, Bonella F, Li W, Boerner EB, Guo Q, Kong X, Zhang X, Costabel U, Kreuter M.

Respiration. 2018;96(6):571-587. doi: 10.1159/000492336. Epub 2018 Oct 11. Review.

PMID:
30308515
10.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V.

BMJ Open Respir Res. 2018 Sep 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. eCollection 2018.

11.

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.

Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M.

Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14.

PMID:
30224318
12.

Should Patients With Interstitial Lung Disease Be Seen by Experts?

Cottin V, Castillo D, Poletti V, Kreuter M, Corte TJ, Spagnolo P.

Chest. 2018 Sep;154(3):713-714. doi: 10.1016/j.chest.2018.05.044. No abstract available.

PMID:
30195349
13.

Interstitial lung diseases: course report.

Kreuter M, Calaras D.

Breathe (Sheff). 2018 Sep;14(3):184-185. doi: 10.1183/20734735.019718.

14.

Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis.

Kwapiszewska G, Gungl A, Wilhelm J, Marsh LM, Thekkekara Puthenparampil H, Sinn K, Didiasova M, Klepetko W, Kosanovic D, Schermuly RT, Wujak L, Weiss B, Schaefer L, Schneider M, Kreuter M, Olschewski A, Seeger W, Olschewski H, Wygrecka M.

Eur Respir J. 2018 Nov 22;52(5). pii: 1800564. doi: 10.1183/13993003.00564-2018. Print 2018 Nov.

PMID:
30166321
15.

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.

Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD.

Respiration. 2018;96(6):514-524. doi: 10.1159/000490667. Epub 2018 Aug 16.

PMID:
30114692
16.

Moderators of Establishing a Smoke-Free Home: Pooled Data from Three Randomized Controlled Trials of a Brief Intervention.

Kegler MC, Haardörfer R, Bundy LT, Escoffery C, Williams RS, Hovell M, Kreuter M, Mullen PD.

J Community Health. 2019 Feb;44(1):121-126. doi: 10.1007/s10900-018-0561-6.

PMID:
30101386
17.

A Face-Aging Smoking Prevention/Cessation Intervention for Nursery School Students in Germany: An Appearance-Focused Interventional Study.

Brinker TJ, Alfitian J, Seeger W, Groneberg DA, von Kalle C, Enk AH, Herth FJF, Kreuter M, Bauer CM, Gatzka M, Suhre JL.

Int J Environ Res Public Health. 2018 Aug 4;15(8). pii: E1656. doi: 10.3390/ijerph15081656.

18.

Gazing into the crystal ball: can treatment response be predicted in IPF?

Kreuter M, Maher T.

Lancet Respir Med. 2018 Aug;6(8):570-572. doi: 10.1016/S2213-2600(18)30234-0. Epub 2018 Jun 29. No abstract available.

19.

Perceptions of Health Coaching for Behavior Change Among Medicaid and Commercially Insured Adults.

McQueen A, Kreuter M, Loughran M, Thompson T, Poor T.

Health Promot Pract. 2018 Aug 1:1524839918790936. doi: 10.1177/1524839918790936. [Epub ahead of print]

PMID:
30064265
20.

Management of Spontaneous Pneumothorax and Postinterventional Pneumothorax: German S3-Guideline.

Schnell J, Beer M, Eggeling S, Gesierich W, Gottlieb J, Herth F, Hofmann HS, Jany B, Kreuter M, Ley-Zaporozhan J, Scheubel R, Walles T, Wiesemann S, Worth H, Stoelben E.

Zentralbl Chir. 2018 Aug;143(S 01):S12-S43. doi: 10.1055/a-0588-4444. Epub 2018 Jul 24. English, German.

PMID:
30041262
21.

Management of Spontaneous Pneumothorax and Post-Interventional Pneumothorax: German S3 Guideline.

Schnell J, Beer M, Eggeling S, Gesierich W, Gottlieb J, Herth FJF, Hofmann HS, Jany B, Kreuter M, Ley-Zaporozhan J, Scheubel R, Walles T, Wiesemann S, Worth H, Stoelben E.

Respiration. 2018 Jul 24:1-33. doi: 10.1159/000490179. [Epub ahead of print]

PMID:
30041191
22.

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.

Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, Kopf S, Weycker D, Kirchgaessler KU, Ryerson CJ.

Respiration. 2018;96(4):314-322. doi: 10.1159/000489668. Epub 2018 Jul 19.

PMID:
30025392
23.

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.

Vancheri C, Kreuter M, Richeldi L, Quaresma M, Stowasser S, Wuyts WA.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1105-1106. doi: 10.1164/rccm.201806-1116LE. No abstract available.

PMID:
30025211
24.

Gastro-oesophageal reflux and idiopathic pulmonary fibrosis: the heart burn in patients with IPF can no longer be silent.

Kreuter M, Raghu G.

Eur Respir J. 2018 Jun 21;51(6). pii: 1800921. doi: 10.1183/13993003.00921-2018. Print 2018 Jun. No abstract available.

PMID:
29929960
25.

Breathlessness and Restrictive Lung Disease: An Important Diabetes-Related Feature in Patients with Type 2 Diabetes.

Kopf S, Groener JB, Kender Z, Fleming T, Brune M, Riedinger C, Volk N, Herpel E, Pesta D, Szendrödi J, Wielpütz MO, Kauczor HU, Katus HA, Kreuter M, Nawroth PP.

Respiration. 2018;96(1):29-40. doi: 10.1159/000488909. Epub 2018 Jun 6.

PMID:
29874679
26.

Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L.

Szentes BL, Kreuter M, Bahmer T, Birring SS, Claussen M, Waelscher J, Leidl R, Schwarzkopf L.

Respir Res. 2018 May 25;19(1):101. doi: 10.1186/s12931-018-0808-x.

27.

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L.

JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.

28.

What would help low-income families?: Results from a North American survey of 2-1-1 helpline professionals.

Thompson T, Roux AM, Kohl PL, Boyum S, Kreuter MW.

J Child Health Care. 2018 Jan 1:1367493518777152. doi: 10.1177/1367493518777152. [Epub ahead of print]

PMID:
29788775
29.

Cessation and reduction in smoking behavior: impact of creating a smoke-free home on smokers.

Haardörfer R, Kreuter M, Berg CJ, Escoffery C, Bundy LT, Hovell M, Mullen PD, Williams R, Kegler MC.

Health Educ Res. 2018 Jun 1;33(3):256-259. doi: 10.1093/her/cyy014.

PMID:
29788227
30.

C-proSP-B: A Possible Biomarker for Pulmonary Diseases?

Kahn N, Rossler AK, Hornemann K, Muley T, Grünig E, Schmidt W, Herth FJF, Kreuter M.

Respiration. 2018;96(2):117-126. doi: 10.1159/000488245. Epub 2018 May 15.

PMID:
29763900
31.

Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita.

Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, Blau W, Kreuter M, Rosewich M, Corbacioglu S, Beck J, Schwarz M, Bittenbring J, Radsak MP, Wilk CM, Koschmieder S, Begemann M, Kurth I, Schemionek M, Brümmendorf TH, Beier F.

Leukemia. 2018 Aug;32(8):1762-1767. doi: 10.1038/s41375-018-0125-x. Epub 2018 Apr 2.

PMID:
29749397
32.

Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis.

Schwarzkopf L, Witt S, Waelscher J, Polke M, Kreuter M.

Respir Res. 2018 Apr 25;19(1):73. doi: 10.1186/s12931-018-0769-0.

33.

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Brunnemer E, Wälscher J, Tenenbaum S, Hausmanns J, Schulze K, Seiter M, Heussel CP, Warth A, Herth FJF, Kreuter M.

Respiration. 2018;95(5):301-309. doi: 10.1159/000485933. Epub 2018 Feb 28.

34.

[DGP Interstitial Lung Disease Patient Questionnaire].

Kreuter M, Ochmann U, Koschel D, Behr J, Bonella F, Claussen M, Costabel U, Jungmann S, Kolb M, Nowak D, Petermann F, Pfeiffer M, Polke M, Prasse A, Schreiber J, Wälscher J, Wirtz H, Kirsten D.

Pneumologie. 2018 Jun;72(6):446-457. doi: 10.1055/s-0044-100207. Epub 2018 Feb 21. German.

PMID:
29466814
35.

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions.

Ferrara G, Luppi F, Birring SS, Cerri S, Caminati A, Sköld M, Kreuter M.

Eur Respir Rev. 2018 Feb 7;27(147). pii: 170076. doi: 10.1183/16000617.0076-2017. Print 2018 Mar 31. Review.

36.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.

PMID:
29414827
37.

Patient participation from the perspective of staff members working in spinal cord injury rehabilitation.

Melin J, Persson LO, Taft C, Kreuter M.

Spinal Cord. 2018 Jun;56(6):614-620. doi: 10.1038/s41393-018-0061-7. Epub 2018 Jan 24.

PMID:
29367656
38.

German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.

Behr J, Günther A, Bonella F, Geißler K, Koschel D, Kreuter M, Prasse A, Schönfeld N, Sitter H, Müller-Quernheim J, Costabel U.

Pneumologie. 2018 Feb;72(2):155-168. doi: 10.1055/s-0043-123035. Epub 2018 Jan 16.

39.

Patients with IPF and lung cancer: diagnosis and management.

Tzouvelekis A, Spagnolo P, Bonella F, Vancheri C, Tzilas V, Crestani B, Kreuter M, Bouros D.

Lancet Respir Med. 2018 Feb;6(2):86-88. doi: 10.1016/S2213-2600(17)30478-2. Epub 2017 Dec 11. Review. No abstract available.

PMID:
29241977
40.

Echinacea purpurea Protects Against Restraint Stress-Induced Immunosuppression in BALB/c Mice.

Park S, Lee MS, Jung S, Lee S, Kwon O, Kreuter MH, Perrinjaquet-Moccetti T, Min B, Yun SH, Kim Y.

J Med Food. 2018 Mar;21(3):261-268. doi: 10.1089/jmf.2017.4073. Epub 2017 Dec 7.

PMID:
29215298
41.

CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.

Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W.

Lung Cancer. 2017 Nov;113:121-127. doi: 10.1016/j.lungcan.2017.09.013. Epub 2017 Sep 22.

PMID:
29110838
42.

Implementing an Evidence-based Tobacco Control Program at Five 2-1-1 Call Centers: An Evaluation Using the Consolidated Framework for Implementation Research.

Thompson T, Kreuter MW, Caito N, Williams RS, Escoffery C, Fernandez ME, Kegler MC.

Nicotine Tob Res. 2019 Jan 4;21(2):180-187. doi: 10.1093/ntr/ntx232.

43.

Palliative care in interstitial lung disease: living well.

Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, Brown CE, Calligaro G, Cassidy N, Corte TJ, Geissler K, Hassan AA, Johannson KA, Kairalla R, Kolb M, Kondoh Y, Quadrelli S, Swigris J, Udwadia Z, Wells A, Wijsenbeek M.

Lancet Respir Med. 2017 Dec;5(12):968-980. doi: 10.1016/S2213-2600(17)30383-1. Epub 2017 Oct 13. Review.

44.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

45.

Perceived social support in African American breast cancer patients: Predictors and effects.

Thompson T, Pérez M, Kreuter M, Margenthaler J, Colditz G, Jeffe DB.

Soc Sci Med. 2017 Nov;192:134-142. doi: 10.1016/j.socscimed.2017.09.035. Epub 2017 Sep 22.

46.

The threat in chronic lung diseases: acute exacerbations.

Kreuter M, Cottin V.

Eur Respir Rev. 2017 Sep 27;26(145). pii: 170075. doi: 10.1183/16000617.0075-2017. Print 2017 Sep 30. No abstract available.

47.

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC.

PMID:
28889759
48.

Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.

Behr J, Neuser P, Prasse A, Kreuter M, Rabe K, Schade-Brittinger C, Wagner J, Günther A.

BMC Pulm Med. 2017 Sep 6;17(1):122. doi: 10.1186/s12890-017-0462-y.

49.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

PMID:
28860269
50.

Show Me My Health Plans: Using a Decision Aid to Improve Decisions in the Federal Health Insurance Marketplace.

Politi MC, Kuzemchak MD, Liu J, Barker AR, Peters E, Ubel PA, Kaphingst KA, McBride T, Kreuter MW, Shacham E, Philpott SE.

MDM Policy Pract. 2016 Jul;1. doi: 10.1177/2381468316679998. Epub 2016 Nov 16.

Supplemental Content

Loading ...
Support Center